Showing results (71-80 of 88) with videos related to

Sort By:
Pageof 9
Gastroenterology|June 14, 2021
Evidence-Based Management of Hepatocellular Carcinoma: Systematic Review and Meta-analysis of Randomized Controlled Trials (2002-2020)Philipp K Haber, Marc Puigvehí, Florian Castet, et al.
Journal of Clinical Medicine|February 13, 2021
Predicting the Risk of Postoperative Complications in Patients Undergoing Minimally Invasive Resection of Primary Liver TumorsPhilipp K Haber, Christoph Maier, Anika Kästner, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|December 15, 2021
Objective Response Predicts Survival in Advanced Hepatocellular Carcinoma Treated with Systemic TherapiesMasatoshi Kudo, Robert Montal, Richard S Finn, et al.
Langenbeck'S Archives of Surgery|May 29, 2023
Robotic versus laparoscopic versus open major hepatectomy - an analysis of costs and postoperative outcomes in a single-center settingSebastian Knitter, Linda Feldbrügge, Nora Nevermann, et al.
Journal of Molecular Medicine (Berlin, Germany)|February 5, 2017
Prolylcarboxypeptidase deficiency is associated with increased blood pressure, glomerular lesions, and cardiac dysfunction independent of altered circulating and cardiac angiotensin IIChristoph Maier, Ines Schadock, Philipp K Haber, et al.
American Journal of Transplantation : Official Journal of the American Society of Transplantation and the American Society of Transplant Surgeons|August 23, 2019
Liver transplant for hepatocellular carcinoma in the United States: Evolving trends over the last three decadesMarc Puigvehí, Dana Hashim, Philipp K Haber, et al.
Oncogene|October 24, 2020
Mutations in circulating tumor DNA predict primary resistance to systemic therapies in advanced hepatocellular carcinomaJohann von Felden, Amanda J Craig, Teresa Garcia-Lezana, et al.
Hepatology (Baltimore, Md.)|June 22, 2021
Immunomodulatory Effects of Lenvatinib Plus Anti-Programmed Cell Death Protein 1 in Mice and Rationale for Patient Enrichment in Hepatocellular CarcinomaLaura Torrens, Carla Montironi, Marc Puigvehí, et al.
Hepatology International|March 7, 2026
Immune biomarkers predicting response to G-CSF in acute-on-chronic liver failure: results from a GRAFT trial sub-studyKatrin Splith, Nadja Berndt, Philipp K Haber, et al.
Gut|May 18, 2022
Novel microenvironment-based classification of intrahepatic cholangiocarcinoma with therapeutic implicationsMiguel A Martin-Serrano, Benjamin Kepecs, Miguel Torres-Martin, et al.
Pageof 9